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The tegumental allergen-like (TAL) proteins from Schistosoma mansoni are part of a family of calcium
binding proteins found only in parasitic flatworms. These proteins have attracted interest as potential
drug or vaccine targets, yet comparatively little is known about their biochemistry. Here, we compared
the biochemical properties of three members of this family: SmTAL1 (Sm22.6), SmTAL2 (Sm21.7) and
SmTAL3 (Sm20.8). Molecular modelling suggested that, despite similarities in domain organisation, there
are differences in the three proteins’ structures. SmTAL1 was predicted to have two functional calcium
binding sites and SmTAL2 was predicted to have one. Despite the presence of two EF-hand-like struc-
tures in SmTAL3, neither was predicted to be functional. These predictions were confirmed by native gel
electrophoresis, intrinsic fluorescence and differential scanning fluorimetry: both SmTAL1 and SmTAL2
are able to bind calcium ions reversibly, but SmTAL3 is not. SmTAL1 is also able to interact with man-
ganese, strontium, iron(II) and nickel ions. SmTAL2 has a different ion binding profile interacting with
cadmium, manganese, magnesium, strontium and barium ions in addition to calcium. All three proteins
form dimers and, in contrast to some Fasciola hepatica proteins from the same family; dimerization is not
affected by calcium ions. SmTAL1 interacts with the anti-schistosomal drug praziquantel and the
calmodulin antagonists trifluoperazine, chlorpromazine and W7. SmTAL2 interacts only with W7.
SmTAL3 interacts with the aforementioned calmodulin antagonists and thiamylal, but not praziquantel.
Overall, these data suggest that the proteins have different biochemical properties and thus, most likely,
different in vivo functions.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Schistosomiasis (or bilharzia) is the most common cause of
death from a parasitic disease after malaria [1,2]. Infection with
blood flukes from the genus Schistosoma affects approximately 230
million people, primarily in tropical regions [3,4]. The disease can
be treated effectively with the drug praziquantel (PZQ) [5]. The
mechanism of action of this drug is currently unknown although
evidence suggests that it acts to disrupt calcium signalling pro-
cesses in the fluke, possibly through the antagonism of voltage-
gated ion channels [6,7]. Alternative mechanisms of action whichs, Queen's University Belfast,
BL. UK. Tel.: þ44 (0) 28 9097
r B.V. This is an open access articlhave been proposed include antagonism of adenosine uptake and
interference with the function of myosin regulatory light chains
[8,9]. Although resistance to PZQ has been generated under labo-
ratory conditions, there are as yet no definitive reports of the
emergence of resistance in clinical conditions [10,11]. Resistance to
oxamniquine, an alternative drug for the treatment of Schistosoma
mansoni infections, has been reported [12]. Other helminth para-
sites have also demonstrated the ability to evolve resistance to
commonly used drugs. For example, there are now numerous re-
ports that liver fluke Fasciola hepatica can become resistant to tri-
clabendazole and various species of intestinal nematodes have
developed resistance to ivermectin [13,14]. Thus, it seems likely
that clinically significant resistance to PZQ will, eventually, appear.
Calcium signalling is a key process in all eukaryotic cells [15].
These signalling processes aremediated by calciumbinding proteins,
of which the best characterised is calmodulin [16]. Typically they
coordinate calcium ions using one, or more, EF-hand motifs [17].e under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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changes which alter their interactions with other molecules. In
parasitic platyhelminthes (flatworms) there is an unusual family of
calcium binding proteins which have not been found in any other
group of organisms. These proteins consist of an N-terminal domain
which contains two EF-hand-like structures and a C-terminal dynein
light chain-like (DLC-like) domain. Their functions remain obscure
althoughone report demonstrated thatone familymember (Sm20.8)
interacts with a dynein light chain as part of a larger complex [18].
Many trematode species express several, different members of this
protein family. S. mansoni expresses 13 familymembers [19e23] and
therefore it seems likely that a similar number will be present in
other members of the genus. Some proteins from Schistosoma japo-
nicum and Schistosoma haematobium have already been identified
and characterised [24e27]. F. hepatica and Fasciola gigantica each
express at least four, and familymembershave alsobeen identified in
both Clonorchis sinensis and Opisthorchis viverrini [28e34]. Their
uniqueness to parasitic platyhelminthes and the likelihood that they
are involved in signalling or regulatory processes makes them
attractive potential drug targets. However, there is currently only
limited information about their biochemical properties.
Members of this protein family from Schistosoma spp have been
shown to elicit IgE-mediated immune responses in the host
[23,26,27,35,36]. For this reason, they have been named the teg-
umental allergen-like (TAL) protein family and are considered
promising targets for the development of vaccines against schis-
tosome infection (for example, see Ref. [37]). The first three
members of the family (SmTAL1, SmTAL2 and SmTAL3) were all
discovered independently and given alternative names. Sm22.6
(SmTAL1) has been shown to bind to and inhibit thrombin [38]. The
protein is soluble, but may be associated with membrane proteins
[19]. Its calcium ion and drug binding properties have not been
investigated. No calcium binding was observed with Sm21.7
(SmTAL2) despite the presence of at least one potentially functional
EF-hand [20]. Similarly, blotting with radioactive calcium ions did
not reveal any calcium binding by Sm20.8 (SmTAL3) [21].
Here, we investigated the biochemical properties of SmTAL1,
SmTAL2 and SmTAL3 with particular reference to ion and drug
binding. Our results demonstrate that the biochemical properties of
these three TAL protein family members differ markedly.
2. Materials and methods
2.1. Molecular modelling
Initial homology models were generated using Phyre2 in the
intensive mode [39] and then computationally solvated and energy
minimised using Yasara [40]. Calcium ions were added into both
EF-hands in the SmTAL1 model by aligning it with the calcium-
bound form of the N-terminal domain of soy bean calmodulin
isoform 1 (PDB 2RO8 [41]). A new version of the SmTAL1 pdb file
which included the calcium ion(s) from the aligned protein was
saved and this model was then re-minimised using Yasara. A cal-
cium ion was added into the second EF-hand of SmTAL2 using the
same procedure and the calcium-bound form of a protein-
engineered calcium sensor (PDB 3U0K [42]) as a template. These
proteins were chosen because they were highly ranked, calcium
bound proteins used as templates in the homology modelling
process. The final, minimisedmodels in the apo and calcium-bound
forms are presented as supplementary data to this paper.
2.2. Expression and purification of SmTAL1, SmTAL2 and SmTAL3
Recombinant SmTAL1 (AAA29922.1, Smp_045200.1), SmTAL2
(AAA74050.1, Smp_086480.1) and SmTAL3 (AAC79130.1, Smp_086530.1)were expressed inEscherichia coli asGST-fusionproteins (50
GST) then isolatedonGlutathione-agaroseandcleavedwith thrombin
as previously described [23]. Free GST was removed by passing each
thrombin digest through Q-Sepharose anion exchange beads (Amer-
shamBioscience) equilibratedwith 50mMTris/HCl pH8.0 containing
10mM reduced glutathione. Contaminant thrombinwas removed by
addition of benzamadine-agarose beads (Sigma).
2.3. Native gel electrophoresis
All three SmTAL proteins were resolved in continuous, native gel
electrophoresis. The different physical properties of the proteins
meant that different conditions were required for each. SmTAL1
(17 mM), SmTAL2 (11 mM) or SmTAL3 (32 mM) was incubated at
20 C for 30 min in the presence of EGTA (1 mM) or EGTA (1 mM)/
cation (2 mM). An equal volume (10 ml) of native loading buffer was
added (20% v/v of the appropriate running buffer, 20% v/v glycerol,
5% w/v bromophenol blue, 1% w/v DTT). SmTAL1 was electro-
phoresed on a 6% polyacrylamide gel at pH 8.8 (20mA for 60min on
ice) with a running buffer containing 25 mM TriseHCl, 250 mM
glycine, pH 8.8. SmTAL2 was electrophoresed on a 6% poly-
acrylamide gel at pH 9.4 (20 mA for 90 min on ice) with a running
buffer containing 60 mM Tris, 40 mM CAPS [43]. SmTAL3 was
electrophoresed on 6% polyacrylamide gel at pH 7.4 (20 mA for
80 min on ice) with a running buffer containing 43 mM Imidazole,
35 mM Hepes [43]. Gels were stained with Coomassie blue and
destained with 0.75% (v/v) acetic acid and 0.5% (v/v) ethanol.
2.4. Analytical methods
Differential scanning fluorimetry (DSF) was carried out using
5e7 mM protein in a total volume of 20 ml and the fluorescent dye
Sypro Orange (10  ; manufacturer's concentration definition) as
previously described [44]. Divalent ions or drugs were added as
appropriate. Drugs were initially dissolved in 100% DMSO and
diluted in buffer R (50 mMHepes-OH, pH 7.5, 150 mMNaCl, 10% v/v
glycderol) as required. The concentration of DMSO never exceeded
1% v/v.
Limited proteolysis was carried out using 10e14 mM protein and
20e650 nM protease (trypsin, chymotrypsin or subtilisin) plus
0.8 mM calcium chloride. Reactions (10 ml) were incubated for
approximately 10 min at 37 C before addition of the protease. They
were then incubated for a further 60 min before being stopped by
the addition of an equal volume of SDS-loading buffer (120 mM
TrisHCl pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 5% (w/v) bromo-
phenol blue, 1% (w/v) DTT). Results were analysed by 15% SDS-
PAGE.
Crosslinking with BS3 (50e500 mM) was carried out with
10e14 mM protein (diluted as required in buffer R) in a total volume
of 10 ml. Reaction mixtures were incubated at 37 C for 35 min
before addition of the crosslinker and then incubated at the same
temperature for a further 35 min. EGTA (0.8 mM) or calcium
chloride (1.6 mM) was added as required. Reactions were stopped
by the addition of an equal volume of SDS-loading buffer and
analysed by 15% SDS-PAGE. Control reactions with recombinant
human galactokinase (prepared as previously described [45]) were
carried out using the same protocol.
Intrinsic fluorescence was measured using a Spectra Max
Gemini XS fluorescence platereader fluorimeter and SOFTmax PRO
software. Measurements were taken in triplicate in black 96-well
plates. SmTAL proteins (7e8 mM) were diluted in 10 mM Hepes-
OH, pH 8.8 and calcium chloride (0.8 mM) and/or EGTA (0.4 mM)
were included as required. Fluorescence was excited at 280 nm and
emission measured from 320 to 420 nm. Spectra were corrected by
subtraction of the background spectrum resulting from the same
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as appropriate.
Protein concentrations were determined by the method of
Bradford [46] using BSA as a standard.
3. Results and discussion
3.1. SmTAL proteins show differences in their predicted structures
Homology modelling of the three SmTAL proteins predicted
that, as expected from protein sequence analysis, each protein
consisted of an N-terminal, largely a-helical domain containing two
EF-hand-like structures and a C-terminal, largely b-sheet domain
(Supplementary Figure S1). It should be noted that the linker be-
tween the domains lacks secondary structure, is likely to be flexible
and is unlikely to be predictedwell by themethods used. Therefore,
the orientation of the domainswith respect to each other is likely to
vary as a consequence of the linkers’ flexibilities. The C-terminal
domains resemble the typical structure of a dynein light chain.
Recently a preliminary report of the experimental structure of the
C-terminal domain of SmTAL2 demonstrated that this protein
adopts a DLC-like fold [47], supporting the predictions from our
models. The overall structures of the SmTAL proteins are similar to
those predicted for the F. hepatica proteins FhCaBP3 and FhCaBP4
[30,31].
Despite the similarity in domain organisation, there are some
key differences in the structures. Both SmTAL1 and SmTAL3 form
more extended structures, whereas SmTAL2 is more compact. The
main cause of this difference is the length of the flexible, essentially
unstructured linker between the two domains. In SmTAL1 it is 26
residues long (Ser-76 to Ile-100) and in SmTAL3 it spans 17 residues
(Gln-75 to Ile-91). In contrast the linker in SmTAL2 is only five
residues long (Gly-67 to Asn-71). Consequently, the folded part of
the C-terminal domain in this protein is larger than in the other two
proteins and it is also in closer proximity to the N-terminal domain.
Examination of the structure and sequences of the N-terminal
domains revealed two potential EF-hand calcium binding se-
quences in each of the three proteins. A typical EF-hand is struc-
tured so that six residues can coordinate the calcium ion using a
mixture of side chain and backbone oxygen atoms. The coordi-
nating residues anchor the ion approximately at right angles to
each other and are referred to as X, Y, Z, -X, -Y and -Z [17]. The EF-
hand folds into a loop, with residues not involved in ion binding
facilitating the tight turns necessary for this structure [48]. Bioin-
formatics analyses have revealed preferred residues at each of the
coordinating positions [17].
In SmTAL1, both EF-hands are folded into the typical loop
(Fig. 1). In the first motif, the potentially coordinating residues
conform to the preferred ones, expect at -Y (Met-27, where threo-
nine is preferred). However, this at this position coordination is
provided by the backbone oxygen. In themodel presented here, this
oxygen atom is orientated into the potential ion binding space
(Fig. 1). The second EF-hand in SmTAL1 also has the typical struc-
ture and this motif has preferred residues at all the potentially
coordinating positions. Thus, based on these predictions, both EF-
hands have the potential to be functional calcium binding sites
(Fig. 1).
The first motif in SmTAL2 deviates from both the typical
sequence and structure of an EF-hand. The Z residue (Thr-22,
aspartate preferred) and -Y (Glu-24, threonine preferred) both
deviate from the preferred residues. The predicted structure also
differs from the typical EF-hand fold being elongated in comparison
and partly folded into an a-helix (Fig. 1). It is, therefore, unlikely
that this motif interacts with calcium ions. The second EF-hand in
SmTAL2 conforms to the consensus fold and all the potentiallycoordinating residues are preferred ones. Therefore, this EF-hand is
likely to bind calcium ions (Fig. 1).
Both EF-hands in SmTAL3 deviate considerably from the
consensus. The first EF-hand adopts an elongated structure (similar
to the first EF-hand in SmTAL2) and deviates from the preferred
residue at positions Z (Thr-16) (Fig. 1). The second motif resembles
the fold of a typical EF-hand. However, it differs from the preferred
coordinating residues at Y (Lys-48), Z (Thr-50) and eZ (Thr-56). Of
these, the lysine residue is probably the most significant. It in-
troduces a positive charge into the motif (thus potentially repelling
the cation) and removes one of the coordinating oxygens (Fig. 1).
Therefore it is unlikely, based on this predicted structure, that
either EF-hand in SmTAL3 will be functional as a calcium ion
binding site.
3.2. SmTAL proteins have different divalent cation binding
properties
The three SmTAL proteins were tested for their ability to bind
calcium ions by native gel electrophoresis, intrinsic fluorescence
spectroscopy and DSF. Each protein has different electrophoretic
properties and it was necessary to use different gel systems for each
protein. Based on previous experience with FhCaBP3 [31], the cal-
cium chelating agent EGTA was routinely added to the SmTAL
proteins to remove any calcium ions which bound during recom-
binant expression/purification. Divalent ions were then added in a
two-fold molar excess as required.
SmTAL1's electrophoretic mobility was increased in the pres-
ence of EGTA compared to the untreated protein; addition of cal-
cium ions reduced the mobility to a level similar to that of the
untreated protein (Fig. 2a). Thus, it is likely that the recombinant
protein is largely calcium-bound and that SmTAL1 can reversibly
bind to calcium ions. Similar shifts were also seen following the
addition of manganese, strontium, nickel (II) and, possibly, iron (II)
ions. However, cadmium, magnesium, barium, cobalt (II), copper
(II), zinc, lead (II) and potassium ions did not result in any shift
(Fig. 2a). SmTAL2 shows similar behaviour in the presence of EGTA
or calcium ions (Fig. 2a). Therefore, it too was largely purified in a
calcium-bound state and is capable of reversible binding to calcium
ions. In addition to calcium ions, SmTAL2 also interacted with
cadmium (II), manganese, magnesium and, possibly, strontium and
barium ions (Fig. 2a). Iron (II) and cobalt (II) ions caused some
blurring of the protein on the gel most likely as a result of protein
aggregation or partial unfolding (Fig. 2a). With the exception of
calcium and, perhaps, manganese, it is unlikely that any of the in-
teractions with ions by SmTAL1 and SmTAL2 are physiologically
relevant. Nevertheless, these results illustrate that, despite struc-
turally similar EF-hands (Fig. 1), the two proteins show some
variability in their ion binding properties. In contrast to SmTAL1
and SmTAL2, SmTAL3's mobility was unaffected by EGTA or by
calcium ions. Indeed, none of the ions tested resulted in a shift
similar to those seenwith SmTAL1 or SmTAL2. Cadmium (II), nickel
(II), zinc and lead (II) ions all caused blurring or a substantial shift
suggesting aggregation or partial unfolding (Fig. 2a). These data
suggest that SmTAL3 does not undergo a physiologically relevant,
reversible interaction with any of the ions tested.
All three SmTAL proteins gave the expected fluorescence emis-
sion spectra when excited at 280 nm, ie a broad peak at approxi-
mately 340 nm (Fig. 2b). Spectra were recorded in 0.4 mM EGTA
and in 0.4 mM EGTA/0.8 mM calcium chloride. In the case of
SmTAL1 and SmTAL2, the spectra under these two conditions were
noticeably different and the fluorescence intensity at the maximum
wavelength was statistically significantly different (p < 0.02; un-
paired t-test with Welch's correction). However, in the case of
SmTAL3, there was no noticeable difference in the two spectra and
Fig. 1. EF-hands from the SmTAL proteins. Molecular models of the EF-hand sequences from each of the SmTAL proteins are shown. In each case the potential ion coordinating
residues are shown. For SmTAL1 both EF-hands are shown occupied by a calcium ion. In SmTAL2 only the second EF-hand is shown occupied and in SmTAL3 neither is shown
occupied. These calcium ion occupancies are consistent with predictions based on the structure and sequences, and with the experimental data presented in this paper (see Results
and Discussion).
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sion wavelength (Fig. 2b). These data provide additional evidence
that SmTAL1 and SmTAL2 are calcium ion binding proteins,
whereas SmTAL3 is not.
All three SmTAL proteins showed considerable thermal stability
(Table 1). In the presence of 0.4 mM EGTA (to remove any bound
calcium ions), both SmTAL1 and SmTAL3 hadmelting temperatures
well above the mammalian host body temperature. It was not
possible to obtain reliable melting temperature data for SmTAL2.
The DSF assay measures the increase in dye fluorescence when it is
released from the unfolded protein [49]. With SmTAL2, no such
increase was observed and so it was assumed that its melting
temperature is higher than the limit of the instrument (95 C). Both
SmTAL1 and SmTAL3 showed a single phase thermal denaturation,
suggesting that either the two domains have similar Tm values or
that the proteins unfold in a single transition (which would imply
that the domains contact each other in the native fold). SmTAL1, but
not SmTAL3, was thermally stabilised by the presence of calcium
ions (Fig. 2c; Table 1). Typically, proteins are stabilised by ligands
which bind to the native state. Therefore, this result provides
further evidence that SmTAL1 is a calcium binding proteinwhereasSmTAL3 is not. This experimental finding is consistent with the
bioinformatics and homology modelling analyses which showed
that both EF-hands in SmTAL3 deviated from the consensus (Fig. 1).
Therefore, we conclude that SmTAL1 and SmTAL2 reversibly
interact with calcium (and some other divalent ions) but SmTAL3
does not interact with calcium ions.
3.3. SmTAL proteins have different drug binding properties
The ability of the SmTAL proteins to interact with the calmod-
ulin antagonists chlorpromazine (CPZ), N-(6-Aminohexyl)-5-
chloro-1-naphthalenesulfonamide hydrochloride (W7) and
trifluoperazine (TFP), the anti-schistosomal drug praziquantel and
the barbiturate thiamylal was investigated by limited proteolysis
and DSF. TFP, W7 and CPZ bind to partially overlapping hydro-
phobic pockets in the EF-hand domains of calmodulin [50e53].
Therefore, we hypothesised that they might interact with the
SmTAL proteins through their EF-hand domains. PZQ has been
shown to interact with myosin regulatory light chain (RLC) from
S. mansoni [9]. The binding site has not been mapped. Myosin RLCs
have similar folds to calmodulin and, therefore, we reasoned that
Fig. 2. Ion binding by SmTAL proteins. (a) Native gel electrophoresis of SmTAL1 (17 mM), SmTAL2 (11 mM) and SmTAL3 (32 mM). U, untreated protein; E, protein plus 1 mM EGTA;
various ions as indicated at a concentration of 2 mM ion/1 mM EGTA. For the conditions of electrophoresis see Materials and Methods. Given that the proteins were shown to be
dimeric in crosslinking experiments, it is reasonable to assume that the bands in these native gels also represent dimers. (b) Intrinsic fluorescence spectra of SmTAL1 (7 mM),
SmTAL2 (8 mM) and SmTAL3 (7 mM) in the 0.4 mM EGTA (dashed line) and 0.4 mM EGTA/0.8 mM calcium chloride (solid line). (c) First derivative curves for the thermal denaturation
(“melting”) of SmTAL1 (5 mM) and SmTAL3 (7 mM). Dashed line, protein plus 0.4 mM EGTA; solid line, protein plus 0.4 mM EGTA/0.8 mM calcium chloride.
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partially similar, structures (such as SmTALs). Although thiamylal's
main pharmacological action is as an anaesthetic, it has also been
reported to disrupt the interaction between calmodulin and calci-
neurin, most likely through direct interactionwith calmodulin [54];
however, the binding site on calmodulin has not been determined.
SmTAL1 was partially protected from limited proteolysis by
chymotrypsin by PZQ, CPZ, W7, TFP and, possibly, thiamylal (Fig. 3).Table 1
Melting temperatures (in C; means ± standard deviation) of SmTAL1 (5 mM) and
SmTAL3 (7 mM) (determined by DSF) under various conditions.
SmTAL1 SmTAL3
EGTA (0.4 mM) 58.4 ± 0.5 73.6 ± 0.4
EGTA (0.4 mM)/CaCl2 (0.8 mM) 65.7 ± 0.7a 73.6 ± 0.4
DMSO (1% v/v) 60.3 ± 0.1 74.6 ± 0.1
Praziquantel (0.25 mM) 61.7 ± 0.2b 74.5 ± 0.0
Chlorpromazine (0.25 mM) 61.3 ± 0.3b 74.1 ± 0.1b
W7 (0.25 mM) 61.5 ± 0.3b 74.3 ± 0.1b
Trifluoperazine (0.25 mM) 62.2 ± 0.8b 73.9 ± 0.1b
Thiamylal (0.25 mM) 60.5 ± 0.7 74.5 ± 0.4
a Significantly different (p < 0.05 in an unpaired t-test with Welch's correction)
from the value for the same protein in EGTA only.
b Significantly different (p < 0.05 in an unpaired t-test with Welch's correction)
from the value for the same protein in the presence of DMSO. In the experiments
with drugs, the final concentration of DMSO was 1% v/v. The DMSO control and the
experiments with drugs all contain 0.8 mM calcium chloride.Similar results were observed with subtilisin (Supplementary
Figure S2). This method has been previously used with
calmodulin-like proteins from F. hepatica demonstrating that, as
expected, TFP and W7 interacted with FhCaM1 (which differs from
human calmodulin by just two amino acid residues) [55,56]. The
same drugs, except thiamylal, caused a significant (p < 0.05; un-
paired t-test with Welch's correction) increase in the melting
temperature of the protein compared to the DMSO control (Fig. 3;
Table 1). These data suggest that the drugs interact with SmTAL1
increasing its stability towards both proteolysis and thermal
denaturation as a consequence. Of the drugs tested, only W7 pro-
tected SmTAL2 from limited proteolysis by trypsin or chymotrypsin
(Fig. 3; Supplementary Figure S2). As noted above, it was not
possible to carry out DSF analysis on this protein. Both TFP and
thiamylal protected SmTAL3 from proteolysis by trypsin (Fig. 3).
CPZ, TFP and W7 (but not PZQ or thiamylal) caused a significant
(p < 0.05; unpaired t-test with Welch's correction) decrease in the
melting temperature of SmTAL3 (Fig. 3; Table 1). A decrease in the
melting temperature can arise from the drug binding to partially
folded states and thus destabilising the overall population of pro-
tein molecules [57]. The situation with SmTAL3 is clearly more
complex than with SmTAL1 where the results from limited prote-
olysis and DSF were broadly in agreement. However, the two
techniques measure different consequences of ligand binding and a
negative result does not provide evidence for a lack of a druge-
protein interaction. Furthermore, it is possible for an interacting
Fig. 3. Drug binding by SmTAL proteins. (a) Limited proteolysis of SmTAL1 (14 mM), SmTAL2 (10 mM) and SmTAL3 (13 mM) with chymotrypsin (600 nM), trypsin (120 nM) and
trypsin (650 nM) respectively. M, molecular mass markers (45, 35, 18, 14 kDa); U, untreated protein; þ, protein in the presence of protease. The DMSO control and the reactions in
the presence of drugs all contained 1% v/v DMSO and 0.8 mM calcium chloride. All drugs were present at a concentration of 250 mM and reactions were analysed by 15% SDS-PAGE.
(b) First derivative curves for the thermal denaturation (“melting”) of SmTAL1 (5 mM) and SmTAL3 (7 mM) in the presence of drugs (each 250 mM in the presence of 1% v/v DMSO/
0.8 mM calcium chloride). The vertical dotted lines on the graphs indicate the melting temperature of the protein in the presence of 1% v/v DMSO.
Fig. 4. Dimerisation of the SmTAL proteins. The crosslinking of the SmTAL proteins
by BS3 was monitored by 15% SDS-PAGE. M, molecular mass markers (116, 66, 45, 35,
25, 18 kDa); U, Untreated SmTAL protein (SmTAL1 and SmTAL3, 14 mM; SmTAL2,
10 mM); EGTA, reactions carried out in the presence of 0.8 mM EGTA; Ca2þ, reactions
carried out in 0.8 mM EGTA/1.6 mM calcium chloride; BS3 and associated triangle,
increasing concentrations of the crosslinker (50, 150, 500 mM). As a negative control,
human galactokinase (HsGALK1, 15 mM) was tested under the same conditions.
C.M. Thomas et al. / Biochimie 108 (2015) 40e47 45drug to show a positive result in only one of two experiments;
indeed this has been observed previously with FhCaBP3 using
limited proteolysis and fluorescence quenching [31]. While Tm
values report on the protein's overall stability, proteolytic digestion
reports on events in the immediate vicinity of the protease cleavage
site. Therefore, it is not surprising to observe that TFP causes loss of
overall stability as measured by DSF, while locally rigidifying the
polypeptide backbone (or sterically hindering access to the prote-
ase) in limited proteolysis experiments.
3.4. SmTAL proteins are dimeric
EF-hand containing proteins (e.g calmodulin, S100 family pro-
teins) and dynein light chains can form homodimers [56,58e61].
Previously, it has been shown that FhCaBP3 forms homodimers,
although the extent of dimerization is reduced in the presence of
calcium ions [31]. In contrast, FhCaBP4 has a greater tendency to
form dimers in the presence of calcium ions [30]. All three SmTAL
proteins form dimers in solution as judged by proteineprotein
crosslinking and SmTAL3 forms higher order oligomers (Fig. 4).
Calcium ions did not affect the extent of dimerization by any of the
SmTAL proteins (Fig. 4). Control experiments with human gal-
actokinase, which is known to be monomeric from analytical gel
filtration experiments [62], showed no crosslinking under the same
conditions (Fig. 4). This suggests that, in contrast to FhCaBP3 and
FhCaBP4, calcium controlled dimerization does not form part of the
mechanism of action of the SmTAL proteins and that all three
proteins are likely to function as dimers in vivo.
3.5. Conclusions
Despite similarities in sequence and domain organisation, the
three S. mansoni TAL proteins studied here have different
biochemical properties. While SmTAL1 and SmTAL2 interact with
calcium ions, the altered EF-hand sequences in SmTAL3 mean that
it is unable to do so. The three proteins also have different drug
binding properties: a range of compounds known to interfere with
C.M. Thomas et al. / Biochimie 108 (2015) 40e4746calcium signalling was tested and it was found that each protein
interacted with a different subset of compounds. This demon-
strated that is possible to distinguish between these proteins
pharmacologically. Furthermore, these biochemical differences
suggest that the proteins have different functions in the organism.
Discovering the cellular roles of this family of proteins remains a
major challenge in the field. To date, only one binding partner has
been reported for these proteins: SmTAL3 interacts with a dynein
light chain and, presumably, other unidentified proteins in a 90 kDa
complex [18]. Whether, or not, other members of the SmTAL family
can substitute for SmTAL3 in this complex is not known.
The discovery that SmTAL1 binds to praziquantel is interesting
and it remains to be discovered if this interaction is pharmaco-
logically important. Despite the successful use of this drug for over
three decades, its molecular mechanism of action remains elusive.
The majority of evidence points towards a mechanism which in-
volves the disruption of calcium-mediated processes. The ability of
SmTAL1 to bind calcium ions suggests the hypothesis that prazi-
quantel acts, in part, through antagonism of this protein's activities.
Calmodulin regulates some voltage-gated calcium channels in a
variety of vertebrate and invertebrate species [63]. In some cases
the channel is inactivated by calcium-bound calmodulin [64,65]. It
is tempting to speculate that SmTAL1 (and possibly other members
of this group of proteins) may be able to perform this function in
Platyhelminthes. If this was the case, antagonism of SmTAL1 would
result in dysregulation of the voltage-gated calcium channel and
unregulated influx of calcium ions, in other words, the documented
physiological consequences of PZQ in Schistosoma spp [66]. This
merits further investigation.
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